Covid-19—the law and limits of quarantine WE Parmet, MS Sinha New England Journal of Medicine 382 (15), e28, 2020 | 613 | 2020 |
The Opioid Epidemic: Fixing a Broken Pharmaceutical Market A Sarpatwari, MS Sinha, AS Kesselheim Harv. L. & Pol'y Rev. 11, 463, 2017 | 94 | 2017 |
Regulatory and safety considerations in deploying a locally fabricated, reusable face shield in a hospital responding to the COVID-19 pandemic A Mostaghimi, MJ Antonini, D Plana, PD Anderson, B Beller, EW Boyer, ... Med 1 (1), 139-151. e4, 2020 | 67* | 2020 |
Determinants of market exclusivity for prescription drugs in the United States AS Kesselheim, MS Sinha, J Avorn JAMA Internal Medicine 177 (11), 1658-1664, 2017 | 66 | 2017 |
Novel indole chemistry in the synthesis of heterocycles GW Gribble, MG Saulnier, ET Pelkey, TLS Kishbaugh, Y Liu, J Jiang, ... Current Organic Chemistry 9 (15), 1493-1519, 2005 | 60 | 2005 |
Personal Protective Equipment for COVID-19: Distributed Fabrication and Additive Manufacturing MS Sinha, FT Bourgeois, PK Sorger American journal of public health 110 (8), 1162-1164, 2020 | 49 | 2020 |
Analysis of SteraMist ionized hydrogen peroxide technology in the sterilization of N95 respirators and other PPE AK Cramer, D Plana, H Yang, MM Carmack, E Tian, MS Sinha, ... Scientific reports 11 (1), 2051, 2021 | 47 | 2021 |
Fentanyl panic goes viral: the spread of misinformation about overdose risk from casual contact with fentanyl in mainstream and social media L Beletsky, S Seymour, S Kang, Z Siegel, MS Sinha, R Marino, A Dave, ... International Journal of Drug Policy 86, 102951, 2020 | 45 | 2020 |
Assessing the filtration efficiency and regulatory status of N95s and nontraditional filtering face-piece respirators available during the COVID-19 pandemic D Plana, E Tian, AK Cramer, H Yang, MM Carmack, MS Sinha, ... BMC Infectious Diseases 21, 1-13, 2021 | 36* | 2021 |
Micro‐inequities in Medicine JK Silver, M Rowe, MS Sinha, DM Molinares, ND Spector, D Mukherjee PM&R 10 (10), 1106-1114, 2018 | 36 | 2018 |
A panic foretold: Ebola in the United States WE Parmet, MS Sinha Critical Public Health 27 (1), 148-155, 2017 | 31 | 2017 |
The Perils of Panic: Ebola, HIV, and the Intersection of Global Health and Law MS Sinha, WE Parmet American Journal of Law & Medicine 42 (2-3), 223-255, 2016 | 29 | 2016 |
When Markets Fail JJ Darrow, MS Sinha, AS Kesselheim Food and Drug Law Journal 73 (3), 361-382, 2018 | 27* | 2018 |
Pharmaceutical Policy in the United States in 2019: An Overview of the Landscape and Avenues for Improvement AS Kesselheim, MS Sinha, J Avorn, A Sarpatwari Stan. L. & Pol'y Rev. 30, 421, 2019 | 26 | 2019 |
FDA and EMA biosimilar approvals EH Jung, A Sarpatwari, AS Kesselheim, MS Sinha Journal of general internal medicine 35 (6), 1908-1910, 2020 | 25 | 2020 |
Social media impact of the Food and Drug Administration's drug safety communication messaging about zolpidem: mixed-methods analysis MS Sinha, CC Freifeld, JS Brownstein, MM Donneyong, P Rausch, ... JMIR public health and surveillance 4 (1), e7823, 2018 | 25 | 2018 |
Assessing legal responses to COVID-19 S Burris, S de Guia, L Gable, D Levin, WE Parmet, N Terry 2020). Assessing Legal Responses to COVID-19. Boston: Public Health Law …, 2020 | 23 | 2020 |
Regulatory incentives for antibiotic drug development: A review of recent proposals MS Sinha, AS Kesselheim Bioorganic & medicinal chemistry 24 (24), 6446-6451, 2016 | 23 | 2016 |
Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012 MS Sinha, M Najafzadeh, EK Rajasingh, J Love, AS Kesselheim JAMA internal medicine 178 (11), 1458-1466, 2018 | 20 | 2018 |
A Crisis-Responsive Framework for Medical Device Development Applied to the COVID-19 Pandemic MJ Antonini, D Plana, S Srinivasan, L Atta, A Achanta, H Yang, ... Frontiers in digital health 3, 2021 | 18 | 2021 |